the aid library

LIST OPTIONS

Filter

7720

Sort by:

Direction:

Download (622)

View PDF (957)

Improving Health and Reducing Poverty. Disease Control Priorities, Third Edition : Volume 9.

Jamison, Dean T.; Gelband, Hellen; Horton, Susan, et al. World Bank (2017) CC

As the culminating volume in the DCP3 series, volume 9 will provide an overview of DCP3 findings and methods, a summary of messages and substantive lessons to be taken from DCP3, and a further discussion of cross-cutting and synthesizing topics across the first eight volumes. The introductory chapte... more

Download (284)

View PDF (354)

HTLV-1 Infection and Adult T-Cell Leukemia/Lymphoma - A Tale of Two Proteins: Tax and HBZ

Chou-Zen Giam; Semmes, Oliver John (2016) CC3

published in: Viruses 2016, 8, 161

Download (875)

View PDF (1600)

From Malaria Control to Malaria Elimination: A Manual for Elimination Sce- nario Planning

Justin Cohen, Deepika Kandula, Bruno Moonen et al. World Health Organization WHO (2014)

The elimination scenario planning (ESP) manual provides malaria-endemic countries with a comprehensive framework to assess different scenarios for moving towards this goal, depending on programme coverage and funding availability. It also helps countries set realistic timelines and provides essentia... more

Download (813)

View PDF (1666)

A global brief on vector-borne diseases

World Health Organization (2014) C_WHO

With this World Health Day, WHO is drawing attention to a group of diseases that are spread by insects and other vectors, the heavy health and economic burdens they impose, and what needs to be done to reduce these burdens. Many of these diseases have been historically confined to distinct geographi... more

Download (554)

View PDF (1213)

Risk assessment on yellow fever virus circulation in endemic countries

World Health Organization WHO (2014) C_WHO

Working document from an informal consultation of experts. A Protocol for risk assessment at the field level. The purpose of document is to provide guidance on the methodology to be used for assessing, at field level, the yellow fever virus circulation in areas at risk, and is primarily intended fo... more

Download (942)

View PDF (1593)

Community-Based Care for Drug-Resistant Tuberculosis: A Guide for Implementers

United States Agency for International Development (USAID) (2011)

This guide provides practical, step-by-step guidance on how to organize, implement, and monitor community-based care for DR TB. It is equally useful for program planning or supervision. The target audience for this guide is TB Program Managers, governments, policy makers, nongovernmental organizatio... more

Download (677)

View PDF (498)

National Policy and Strategy for Nursing and Midwifery Services

Islamic Republic of Afghanistan, Ministry of Public Health (2011) C1

Draft May 2011
The first ever nursing and midwifery services policy document in the history of MoPH was developed with the following aims:
1. Create a positive environment for Nursing and Midwifery Policy and Practice
2. Promote education, training and career development for nurses an... more

Download (939)

View PDF (1642)

Engaging Men in HIV and AIDS at the Service Delivery Level: A Manual for Service Providers

EngenderHealthThe ACQUIRE Project (2008)

Designed for trainers of health workers, this manual offers skills-building sessions on developing more “male-friendly” health services. Utilizing participatory and experiential activities, the manual examines attitudinal and structural barriers that inhibit men from seeking HIV and AIDS service... more

Download (725)

View PDF (1588)

District guidelines for yellow fever surveillance

World Health Organization WHO (1998) C_WHO

Download (39)

View PDF (51)

Guidelines for Management of ST-Elevated Myocardial Infarction

Directorate General of Health Services Ministry of Health & Family Welfare Government of India (2022) CC

Myocardial infarctions are generally clinically classified into ST elevation MI (STEMI) and non-ST elevation MI (NSTEMI), based on changes in ECG. When blood flow to a part of the heart stops or the heart is injured and fails to receive enough oxygen required for its adequate functioning the conditi... more

Download (53)

View PDF (53)

Annual Report: Global Polio Eradication Initiative

World Health Organisation (WHO) (2024) CC

The key to a lasting world free of all forms of poliovirus lies in rapidly interrupting all remaining endemic transmission of WPV in the endemic areas of Pakistan and Afghanistan. This is the only way to ensure that such strains do not re-emerge globally through international spread. It lays the cor... more

Download (160)

View PDF (142)

Preparedness and Resilience for Emerging Threats Module 1: Planning for respiratory pathogen pandemics

World Health Organization WHO (2024) C_WHO

Through technical consultations with countries and partners, WHO has led the development of Preparedness and Resilience for Emerging Threats Module 1: Planning for respiratory pathogen pandemics. Version 1.0. The Module, currently available as an advanced draft, builds on previous pandemic lessons a... more

Download (173)

View PDF (246)

Democratic Republic of Timor-Leste Ministry of Health - Comprehensive TB Guidelines for National Tuberculosis Program, V Edition

Government of Timor-Leste; World Health Organization (2023) CC

The Democratic Republic of Timor-Leste has the highest TB incidence rate in the South East Asian Region - 498 per 100,000, which is the seventh highest in the world. In Timor-Leste TB is the eighth most common cause of death. The salient observations are as follows: In 2018, 487 (12.5%) of the... more

Download (273)

View PDF (368)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (117)

View PDF (176)

Предотвращение самоубийств - Глобальный императив

Shekhar Saxena , Etienne Krug, Oleg Chestnov et al. World Health Organization (WHO) (2014) C_WHO

Цель данного доклада – стать ресурсом, позволяющим руководителям и другим заинтересованным сторонам рассматри-вать предупреждение самоубийств как императив. То�... more